Title: The efficacy of 3 years adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance
Abstract: Objective To evaluate the effect of rescue monotherapy of adefovir(ADV) in patients with chronic hepatitis B(CHB) who had developed drug resistance to lamivudine(LAM) and moreover to gain experience of the treatment of LAM resistant.Methods A total of 60 treated CHB patients with LAM resistance were enrolled in the present study.The patients′ baseline characteristics such as age,gender,blood tests and hepatitis B virus(HBV) DNA were collected;therapy duration and the response of each patient were also recorded.Results 20 of 60 cases had HBV DNA quantitative rebound ≥ 1log10copies/ml HBV DNA sequencing rtM204I/V,rtL180M sites of variation were seen in the remaining 40 cases.Biochemical breakthrough was observed in LAM-resistant patients being treated with ADV monotherapy.Completion of 156 weeks of treatment in 42 cases.In low copy HBV DNA group(baseline HBV DNA 103-105 copies /ml)after 12-156 weeks of treatment,HBV DNA negative rates were 80.6%.Whereas in high copy HBV DNA group(baseline HBV DNA≥106 copies /ml),negative rates were 40.7%-44.7%.The two groups had significant differences(P0.01).HBV DNA negative rate gradually increased with prolonged treatment.When the treatment was at 156 week,HBeAg seroconversion rate was 24.1%.Four cases of variant sites detected rtA181V/I/S using ETV.Conclution ADV monotherapy in the treatment of LAM-resistant chronic hepatitis B have certain effect,and is more suitable for patients with low viral load.
Publication Year: 2012
Publication Date: 2012-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot